This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Koch-Henriksen, N. Search for Related Content PubMed PubMed Citation Articles by Koch-Henriksen, N. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis

The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, Department of Neurology, Aalborg Hospital North, Aalborg, Denmark

Per Soelberg Sùrensen

The Copenhagen Multiple Sclerosis Clinic and MS Research Unit, Neuroscience Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

The Danish Multiple Sclerosis Group

After approval by the European Union in 1996 of interferon-beta for treatment of relapsing-remitting multiple sclerosis (RRMS), 862 patients in Denmark have received treatment (by April 1999), and 304 of those were enrolled into an open labelled randomised trial to compare the efficacy and tolerability of treatment with interferon-beta-1b (Betaferon) 8 MIU subcutaneous every other day and interferon-beta-1a (Rebif) 6 MIU subcutaneous once a week. Primary and secondary end-points included: (1) the relapse rate, (2) tolerability, (3) neutralizing antibody formation using the same specialised laboratory and validated assay, (4) time to first relapse, (5) time to sustained progression, and (6) number of gadolinium-enhancing lesions in T1-weighted MRI and the total lesion load in T2-weighted MRI. All the records are kept in a nationwide clinical database connected with the Danish Multiple Sclerosis Registry. The randomised trial will be completed by the end of 1999, and the results are not yet available. The annual relapse rate in all treated patients until April 1999 was 0.73, the annual rate of steroid treated relapses was 0.21. By 1 April 1999 8.8% of the patients had discontinued treatment and 10.4% had changed to another interferon-beta preparation. It has been planned to extend the follow-up of all patients treated according to the Danish National Protocol for a period of several years. The continuous and nation-wide registration of the course of the disease in interferon-beta treated RRMS patients may provide valuable knowledge of the treatment-modified long-term course of the disease in a cohort of patients, selected on the basis of well-defined criteria.

Key Words: multiple sclerosis drug therapy • interferon beta therapeutic use • randomized controlled trials • databases • registries

Multiple Sclerosis, Vol. 6, No. 3, 172-175 (2000)
DOI: 10.1177/135245850000600306


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N Koch-Henriksen, P. Sorensen, K Bendtzen, and E. Flachs The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, May 1, 2009; 15(5): 601 - 605. [Abstract] [PDF]

				P. Sorensen, N. Koch-Henriksen, and K. Bendtzen Are ex vivo neutralising antibodies against IFN-{beta} always detrimental to therapeutic efficacy in multiple sclerosis? Multiple Sclerosis, June 1, 2007; 13(5): 616 - 621. [Abstract] [PDF]

				B. Petersen, K. Bendtzen, N. Koch-Henriksen, M. Ravnborg, C. Ross, P. S. Sorensen, and The Danish Multiple Sclerosis Group Persistence of neutralizing antibodies after discontinuation of IFN{beta} therapy in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 247 - 252. [Abstract] [PDF]

				P. S. Sorensen, N. Koch-Henriksen, M. Ravnborg, J. L. Frederiksen, K a. Jensen, A. Heltberg, H. Schaldemose, S. Deth, O l. Kristensen, M. Worm, et al. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey Multiple Sclerosis, June 1, 2006; 12(3): 253 - 264. [Abstract] [PDF]

				N. Koch-Henriksen, P. S. Sorensen, T. Christensen, J. Frederiksen, M. Ravnborg, K. Jensen, A. Heltberg, O. Kristensen, E. Stenager, T. Petersen, et al. A randomized study of two interferon- beta treatments in relapsing-remitting multiple sclerosis Neurology, April 11, 2006; 66(7): 1056 - 1060. [Abstract] [Full Text] [PDF]

				S L Minden, D Frankel, L Hadden, J Perloff, K P Srinath, and D C Hoaglin The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics Multiple Sclerosis, February 1, 2006; 12(1): 24 - 38. [Abstract] [PDF]

				P. S. Sorensen, N. Koch-Henriksen, C. Ross, K. M. Clemmesen, K. Bendtzen, and the Danish Multiple Sclerosis Study Group Appearance and disappearance of neutralizing antibodies during interferon-beta therapy Neurology, July 12, 2005; 65(1): 33 - 39. [Abstract] [Full Text] [PDF]